CHILDREN'S CANCER GROUP
CHILDREN'S CANCER GROUP
批准号:
2085911
负责人:
JAMES S MISER
金额:
$18.23万
依托单位国家:
美国
项目类别:
财政年份:
1976
资助国家:
美国
项目状态:
已结题
起止时间:
1976-12-01 至 1998-11-30
关键词:
acute nonlymphocytic leukemia bone neoplasms brain neoplasms child (0-11) clinical trials combination cancer therapy combination chemotherapy cooperative study human subject human therapy evaluation longitudinal human study neoplasm /cancer chemotherapy neoplasm /cancer epidemiology neoplasm /cancer immunotherapy neoplasm /cancer radiation therapy neoplasm /cancer surgery neuroblastoma oncology nursing osteosarcoma pathologic process pediatric neoplasm /cancer pharmacy psychosocial service tissue resource /registry
中文摘要
这项建议是为了继续在自然环境中进行合作研究
儿童癌症的历史、流行病学、生物学和治疗
华盛顿州西雅图的儿童医院和医疗中心(CHMC)
儿童癌症组织(CCG)正式成员机构。
这项提议的具体目标是:1)开发更好的治疗方法
儿童癌症;2)更好地了解儿童癌症的生物学
儿童癌症;以及3)更好地了解自然
儿童癌症治疗的历史、流行病学和远期效应。
CHMC将通过将患者捐献到第三阶段来实现这些目标
通过参与CCG试点,进行随机组间和CCG试验
治疗性试验将成为未来随机试验的基础,
通过参与新的药物试验,通过提供样本和数据
用于生物学、流行病学和后遗症研究,并通过提供
领导CCG的科学和管理工作。
在最后一次赠款期间的头三年,即1989、1990和1991年,
248名患者参加了治疗研究,
181个用于流行病学和后遗症研究,36个用于生物学
学习。截至1991年底,有838名患者正在积极跟进
在完成CCG治疗研究后。在1992年的前8个月,
在Miser博士到达CHMC后,97名患者进入CCG
治疗方案(每月12名患者)和83名患者接受非
治疗方案(每月10名患者)。
CHMC是CCG领导层的重要贡献者:Chard博士,
前白血病研究副主席和前副董事长
CCG,是首席调查员,提名委员会成员,
也是一位重要的组长。米瑟博士是CCG执行委员会成员
CCG实体肿瘤研究副主席;
骨肿瘤战略小组;CCG-7881主席,CCG-8605主席,
CCG试点骨肉瘤计划主席,以及多个
其他治疗和策略委员会的成员。盖耶博士是
脑肿瘤战略小组,CCG-9921主席,CCG-0896主席,
CCG-B921主席,以及其他几个脑瘤的成员
委员会。伯恩斯坦博士是生物委员会的成员,
ANLL参考实验室的首席研究员。彭德格拉斯医生
是CCG-8602主席和多个流行病学学会的成员
委员会。米尔斯坦博士和伯杰博士是脑肿瘤协会的成员
委员会。夏勒医生是外科和神经母细胞瘤的成员。
委员会。怀特博士是成像委员会的成员。布雷格博士是
心理学委员会的成员。
英文摘要
This proposal is for continuation of collaborative research in the natural
history, epidemiology, biology, and treatment of childhood cancer at the
Children's Hospital & Medical Center (CHMC) in Seattle, Washington as a
full member institution of the Childrens Cancer Group (CCG).
The specific aims of this proposal are: 1) to develop better treatment of
childhood cancer; 2) to develop a better understanding of the biology of
childhood cancers; and 3) to develop a better understanding of the natural
history, epidemiology, and late effects of treatment of childhood cancer.
CHMC will pursue these aims by contributing patients to phase III
randomized intergroup and CCG trials, by participating in CCG pilot
therapeutic trials that will form the basis for future randomized trials,
by participating in new agent trials, by contributing specimens and data
for biology, epidemiology and late effects studies, and by providing
leadership in the scientific and administrative efforts of CCG.
During the first three years of the last grant period, 1989,1990 and 1991,
two hundred-forty-eight patients were entered onto therapeutic studies,
181 onto epidemiology and late effects studies, and 36 onto biology
studies. At the end of 1991, there were 838 patients in active follow-up
after completing a CCG therapeutic study. In the first 8 months of 1992,
following Dr. Miser's arrival at CHMC, 97 patients were entered onto CCG
therapeutic protocols (12 patients per month) and 83 patients onto non-
therapeutic protocols (10 patients per month).
CHMC is an important contributor to the leadership of CCG: Dr. Chard,
former Associate Chairman for leukemia studies and former vice chairman of
CCG, is the principal investigator, a member of the nominating committee,
and an important group leader. Dr. Miser is a member of the CCG Executive
Committee; Associate Chairman for CCG solid tumor studies; Chairman of the
Bone Tumor Strategy Group; Chairman of CCG-7881, Chairman of CCG-8605,
Chairman of the CCG pilot osteosarcoma program, and a member of a number
of other therapeutic and strategy committees. Dr. Geyer is a member of the
Brain Tumor Strategy Group, Chairman of CCG-9921, Chairman of CCG-0896,
Chairman of CCG-B921, and a member of several other brain tumor
committees. Dr. Bernstein is a member of the biology committee and
principal investigator of the ANLL reference laboratory. Dr. Pendergrass
is Chairman of CCG-8602 and a member of a number of epidemiology
committees. Drs. Milstein and Berger are members of brain tumor
committees. Dr. Schaller is a member of the surgical and neuroblastoma
committees. Dr. White is a member of the imaging committee. Dr. Breiger is
a member of the psychology committee.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IFOSFAMIDE VS VP-16 IN CANCER CHEMOTHERAPY
-
批准号:3865284
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES S MISER
-
依托单位:
IFOSFAMIDE VS VP-16 IN CANCER CHEMOTHERAPY
-
批准号:3886454
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES S MISER
-
依托单位:
IFOSFAMIDE VS VP-16 IN CANCER CHEMOTHERAPY
-
批准号:3850635
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES S MISER
-
依托单位:
海外基金